Core Viewpoint - New Mileage (002219.SZ) announced that its chairman, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties, although the matter is unrelated to the company [1][3] Company Governance and Management - The company has appointed director Xu Minggui to act as chairman during Lin Yanglin's absence, as per the company's articles of association [1] - New Mileage emphasizes its robust governance and internal control mechanisms, stating that other board members and senior management are functioning normally, and the company's operations remain unaffected [3] Business Strategy and Performance - Lin Yanglin has been instrumental in proposing a "comprehensive hospital + specialized branch" chain model to strengthen regional medical center layouts, with 24 hospitals established across six major regions by 2024 [2][4] - The company reported a revenue of 796 million yuan in Q1 2025, a year-on-year decline of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year [3] - New Mileage's net profit saw a significant drop of 80.29% in 2023, followed by a nearly 300% increase in 2024, indicating substantial performance volatility [3] Company Background - New Mileage, originally known as Hengkang Medical Group, was listed on the A-share market in March 2008 and has transitioned from a traditional Chinese medicine manufacturer to a comprehensive healthcare group [3][4] - The company currently operates three tertiary hospitals and 14 secondary hospitals, with nearly 10,000 beds across its facilities [4]